iwCLL 2013: Dr. Jeff Sharman Discusses Two Issues: 17p deletion and Residual Disease in CLL


In Part 6 of my interview from iwCLL, I push Dr. Sharman to spectate on the issues of 17 p deletion and of the importance of residual disease with ibrutinib and idelalisib.

See This is a very interesting segment for me.

Thanks to all who sent well wishes and prayers. While I am not yet well, I am getting better.

Stay strong


1 Reply

  • Many thanks Brian.

    Hope you're feeling better.


You may also like...